1999
DOI: 10.1136/adc.81.5.437
|View full text |Cite
|
Sign up to set email alerts
|

Preliminary report of a toxicity study of hydroxyurea in sickle cell disease

Abstract: Aim-To evaluate the tolerance of hydroxyurea in children aVected with sickle cell disease. Design-Questionnaire study of French physicians likely to treat patients with sickle cell disease. Data were collected on 101 children with sickle cell disease, treated for a median of 22 months, 36 of whom were treated for more than three years. 13 children were younger than 5 years of age at inclusion. Results-Hydroxyurea was stopped for medical reasons in 11 patients: 6 failures, 1 pregnancy, 1 cutaneous rash, 1 leg u… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
31
0
2

Year Published

2000
2000
2023
2023

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 59 publications
(34 citation statements)
references
References 12 publications
1
31
0
2
Order By: Relevance
“…Some studies have shown that HU is genotoxic (Flanagan et al, 2010;Juul et al, 2010;Santos et al, 2011) while other studies suggest that HU has low mutagenicity in vivo (Stricker et al, 1986;Dawkins et al, 1997;Montalembert et al, 1999;Hanft et al, 2000;Montalembert, Davies, 2001;Moschovi et al, 2001). In this study, patients with SCA treated with HU had significantly elevated DI values when compared with the patients with SCA who were not treated with HU.…”
Section: Discussionmentioning
confidence: 99%
“…Some studies have shown that HU is genotoxic (Flanagan et al, 2010;Juul et al, 2010;Santos et al, 2011) while other studies suggest that HU has low mutagenicity in vivo (Stricker et al, 1986;Dawkins et al, 1997;Montalembert et al, 1999;Hanft et al, 2000;Montalembert, Davies, 2001;Moschovi et al, 2001). In this study, patients with SCA treated with HU had significantly elevated DI values when compared with the patients with SCA who were not treated with HU.…”
Section: Discussionmentioning
confidence: 99%
“…These events occurred most often in patients who were currently receiving interferon or had a history of interferon therapy. There is one report of a cutaneous rash in a child, but details of this have not been described [10]. In patients with myeloproliferative disorders severe cutaneous and mucosal reactions have been reported and include skin atrophy with associated telangiectasias, dryness, hyperpigmentation of nails, skin, mucosal, stomatitis, glossitis, actinic keratosis, alopecia, melanonychia, squamous cell carcinomas of sun exposed areas, keratoacanthomas, acral erythema, dermatomyositislike changes of hands and ulcers of skin and mucous membranes [11][12][13].…”
Section: Introductionmentioning
confidence: 99%
“…5 Whereas HU clinical benefits in severely affected adult SCD patients were confirmed by a randomized controlled trial in 1995 (MSH), 1,6 its role in very young children requires further studies. 2,[7][8][9][10] Unanswered questions remain about its sustained efficacy and long-term safety, especially in children who might be exposed to HU for decades. Since our publication in 2001, 2 inclusion of patients in the Belgian Registry of SCD patients treated by HU has been ongoing.…”
Section: Introductionmentioning
confidence: 99%